RSウイルス感染症治療薬の世界市場2016-2020

【英語タイトル】Global Human Respiratory Syncytial Virus Drugs Market 2016-2020

Technavioが出版した調査資料(IRTNTR11070)・商品コード:IRTNTR11070
・発行会社(調査会社):Technavio
・発行日:2016年12月9日
・ページ数:74
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後24時間以内)
・調査対象地域:グローバル
・産業分野:製薬
◆販売価格オプション(消費税別)
Single User(1名利用)USD2,500 ⇒換算¥260,000見積依頼/購入/質問フォーム
Five User(~5名利用)USD3,000 ⇒換算¥312,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD4,000 ⇒換算¥416,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
当調査レポートでは、RSウイルス感染症治療薬の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、市場概観、業界の構造分析、疾患概要、RSウイルス感染症治療薬の世界市場規模及び予測、カテゴリー別分析、市場シェア、地域別分析/市場規模、購買基準、市場の成長要因、市場の課題、製品パイプライン分析、市場動向、競争状況、主要企業(ベンダー)分析などの情報をお届けいたします。
【レポートの概要】

About Human Respiratory Syncytial Virus Drugs
Respiratory syncytial virus (RSV) is a virus that leads to infections in the lungs and the respiratory tract. It commonly affects most children in the ages 2 or below. RSV can also infect adults. In adults and the older population, the symptoms of RSV are mild and similar to that of common cold. Infection with RSV can be severe in certain cases, particularly in premature infants and babies with underlying health conditions. RSV can also become serious in the older population or adults with heart and lung diseases, or any individual with a very weak immune system.

Technavio’s analysts forecast the global human respiratory syncytial virus drugs market to grow at a CAGR of 4.27% during the period 2016-2020.

[Covered in this report]
The report covers the present scenario and the growth prospects of the global human respiratory syncytial virus drugs market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of branded and generic drugs used to treat and prevent respiratory syncytial virus infections.

The market is divided into the following segments based on geography:
• Europe
• ROW
• US

Technavio’s report, Global Human Respiratory Syncytial Virus Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key vendors]
• AstraZeneca
• AbbVie
• GSK
• Teva Pharmaceutical

[Other prominent vendors]
• Ablynx
• ADMA Biologics
• Alnylam Pharmaceuticals
• Ark Biosciences
• Aviragen Therapeutics
• Bavarian Nordic
• Boehringer Ingelheim
• Gilead Sciences
• ImmunoVaccine Technologies
• Johnson & Johnson
• Kyowa Hakko Kirin
• Medivir
• Mucosis
• Mymetics Corporation
• Novavax
• Regeneron Pharmaceuticals
• ReViral
• Vaxart

[Market driver]
• Novel diagnostic tools increase patient population.
• For a full, detailed list, view our report

[Market challenge]
• Continuous change in guidelines from healthcare organizations impacts market growth.
• For a full, detailed list, view our report

[Market trend]
• Emergence of new entrants likely to change market dynamics.
• For a full, detailed list, view our report

[Key questions answered in this report]
• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

※You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

【レポートの目次】

Table of Contents
PART 01: Executive summary
• Highlights

PART 02: Scope of the report
• Market overview
• Top-vendor offerings

PART 03: Market research methodology
• Research methodology
• Economic indicators

PART 04: Introduction
• Key market highlights

PART 05: Disease overview
• Understanding the disease
• Symptoms
• Causes
• Risk factors
• Complications
• Tests and diagnosis
• Key buying criteria

PART 06: Pipeline analysis

PART 07: Market landscape
• Global respiratory syncytial virus drugs market
• Five forces analysis

PART 08: Market segmentation by category of drug
• Approved Drugs
• Off-label drugs

PART 09: Geographical segmentation
• Human respiratory syncytial virus drugs market in US
• Human respiratory syncytial virus drugs market in Europe
• Human respiratory syncytial virus drugs market in ROW

PART 10: Market drivers
• Presence of large patient pool fuels market growth
• Launch of novel products
• Novel diagnostic tools increase patient population

PART 11: Impact of drivers

PART 12: Market challenges
• Continuous change in guidelines from healthcare organizations impacts market growth
• Cyclical nature of market hinders growth opportunities
• Limited drugs in market leading to low penetration rates

PART 13: Impact of drivers and challenges

PART 14: Market trends
• Emergence of new entrants likely to change market dynamics
• Growing strategic collaborations fostering innovation
• Active participation from emerging economies toward R&D

PART 15: Vendor landscape
• Competitive scenario

PART 16: Key vendor analysis
• AstraZeneca
• AbbVie
• GSK
• Teva Pharmaceutical
• Other prominent vendors

PART 17: Appendix
• List of abbreviations

PART 18: Explore Technavio

[List of Exhibits]

Exhibit 01: Product offerings
Exhibit 02: Key customer segments of global human respiratory syncytial virus drugs market
Exhibit 03: Snapshot of RSV infection
Exhibit 04: Key buying criteria for RSV drugs
Exhibit 05: Factors affecting the adoption rates of RSV drugs
Exhibit 06: Pipeline analysis of key vendors in global human respiratory syncytial virus drugs market
Exhibit 07: Percentage share of drug candidates by stage of development
Exhibit 08: Pipeline candidates: Global human respiratory syncytial virus drugs market
Exhibit 09: Global human respiratory syncytial virus drugs market snapshot
Exhibit 10: Analysis of global human respiratory syncytial drugs market
Exhibit 11: Global human respiratory syncytial virus drugs market 2015-2020 ($ billions)
Exhibit 12: Emerging vendors and their initiatives
Exhibit 13: Opportunity analysis of global respiratory syncytial virus drugs market
Exhibit 14: Opportunity analysis in developed and emerging markets
Exhibit 15: Five forces analysis
Exhibit 16: Segmentation of global human respiratory syncytial virus drugs market by type of drug 2015
Exhibit 17: Segmentation of global human respiratory syncytial virus drugs market based on geography 2015 and 2020
Exhibit 18: Global human respiratory syncytial virus drugs market revenue by geography 2015-2020 ($ millions)
Exhibit 19: Incidence of RSV infections in US (on average every year)
Exhibit 20: Global human respiratory syncytial virus drugs market in US 2015-2020 ($ millions)
Exhibit 21: Key drivers and challenges in US
Exhibit 22: Human respiratory syncytial virus drugs market in Europe 2015-2020 ($ millions)
Exhibit 23: Trends in global human respiratory syncytial drugs market in Europe
Exhibit 24: Global human respiratory syncytial virus drugs market in ROW 2015-2020 ($ millions)
Exhibit 25: Key drivers and challenges in ROW
Exhibit 26: Trends in RSV epidemics
Exhibit 27: Potential products
Exhibit 28: Impact of drivers
Exhibit 29: Change in guidelines of AAPCID and its consequences
Exhibit 30: Impact of cyclical nature of RSV epidemics
Exhibit 31: Factors affecting penetration rates
Exhibit 32: Forcefield analysis of drivers and challenges in global human respiratory syncytial virus drugs market
Exhibit 33: Impact of drivers and challenges
Exhibit 34: Potential entrants
Exhibit 35: Strategic alliances
Exhibit 36: Competitive structure analysis of global human respiratory syncytial virus drugs market 2015
Exhibit 37: Market share analysis 2015
Exhibit 38: Market penetration of various RSV drug manufacturers in global human respiratory syncytial virus drugs market (2015)
Exhibit 39: Strategic success factors of companies in global human respiratory syncytial virus drugs market
Exhibit 40: AstraZeneca: Key highlights
Exhibit 41: AstraZeneca: Strength assessment
Exhibit 42: AstraZeneca: Strategy assessment
Exhibit 43: AstraZeneca: Opportunity assessment
Exhibit 44: AstraZeneca: Revenue of Synagis 2013-2015 ($ billions)
Exhibit 45: AstraZeneca: Geographic segmentation of Synagis 2015
Exhibit 46: AbbVie: Strength assessment
Exhibit 47: AbbVie: Strategy assessment
Exhibit 48: AbbVie: Opportunity assessment
Exhibit 49: AbbVie: Revenue of Synagis 2013-2015 ($ millions)
Exhibit 50: GSK: Profile
Exhibit 51: GSK: Strength assessment
Exhibit 52: GSK: Strategy assessment
Exhibit 53: GSK: Opportunity assessment
Exhibit 54: GSK: Revenue of Ventolin 2013-2015 ($ billions)
Exhibit 55: GSK: Geographical segmentation of Ventolin 2015
Exhibit 56: Teva Pharmaceutical: Profile
Exhibit 57: Teva Pharmaceutical: Strength assessment
Exhibit 58: Teva Pharmaceutical strategy assessment
Exhibit 59: Teva Pharmaceutical: Opportunity assessment
Exhibit 60: Teva Pharmaceuticals: YoY revenue and growth rate of ProAir 2013-2015 ($ millions)



【掲載企業】

Other Prominent Vendors in the market are: Askon Engineers, Bio JetDrier, HOKWANG INDUSTRIES, Taishan Jieda Electrical Industrial, Panasonic, and Palmer Fixture.

【レポートのキーワード】

RSウイルス感染症、RSV治療薬、医薬品

【調査方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

★調査レポート[RSウイルス感染症治療薬の世界市場2016-2020] (コード:IRTNTR11070)販売に関する免責事項を必ずご確認ください。
★調査レポート[RSウイルス感染症治療薬の世界市場2016-2020]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆